Printer Friendly

Production of hepatitis a vaccine delayed, orders temporarily halted.

A production delay has caused Merck & Co. to temporarily stop accepting orders for the company's pediatric and adult vial formulations of Vaqta, the hepatitis A vaccine.

It is estimated that the pediatric formulation of Vaqta will be available in the early third quarter of 2008, while the adult formulation will be available in the fourth quarter of 2008.

In the meantime, the Centers for Disease Control and Prevention has reported that the pediatric formulation and adult formulation of GlaxoSmithKline's hepatitis A vaccine Havrix, and its adult hepatitis A/hepatitis B combination vaccine (Twinrix), "are currently in good supply to meet demand."

GlaxoSmithKline plans to increase production of both vaccines to help ensure uninterrupted supply for the United States market.

There has been no change in the routine recommendations for hepatitis A vaccinations, the CDC said.
COPYRIGHT 2008 International Medical News Group
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2008 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Title Annotation:Infectious Diseases
Author:Brunk, Doug
Publication:Internal Medicine News
Date:Mar 15, 2008
Words:135
Previous Article:Antiretroviral therapy may convey metabolic risks.
Next Article:Statin use linked to better heart failure survival.
Topics:


Related Articles
U.S. Centers for Disease Control And Prevention Awards SmithKline Beecham Contract for Hepatitis B Adult Vaccine
CRUCELL/AERAS START TURBERCULOSIS VACCINE CLINICAL TRIAL.
Inovio Biomedical Corp. Partner in Sweden Files Application for Hepatitis C Study.
Inovio Biomedical to Present at American Society of Gene Therapy Meeting.

Terms of use | Copyright © 2018 Farlex, Inc. | Feedback | For webmasters